Armata Pharmaceuticals (TG1N) Price & Analysis

1 Followers

TG1N Stock Chart & Stats

€4.54

€0.00(0.00%)

At close: Jul 24 4:00 PM EDT

€4.54

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€1.97 - €12.70

Previous CloseN/A

Volume0.00

Average Volume (3M)28.00

Market Cap

€177.34M

Enterprise Value€692.03

Total Cash (Recent Filing)€23.95M

Total Debt (Recent Filing)€313.95M

Price to Earnings (P/E)―

Beta1.51

Next Earnings

Nov 18, 2026

EPS Estimate

-0.35

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-5.30

Shares Outstanding37,181,980

10 Day Avg. Volume0

30 Day Avg. Volume28

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-1.04

Price to Sales (P/S)46.41

P/FCF Ratio-8.65

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€12.85

Price Target Upside183.12% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-3.29

Revenue Forecast (FY)€1.90M

Bulls Say, Bears Say

Bulls Say

Phase 3 ReadinessAP-SA02 has advanced from mid-stage development toward a pivotal trial, with regulatory responses addressed and manufacturing preparation underway. This milestone can improve the company’s path toward registration and commercial validation if Phase 3 execution succeeds.

Regulatory ExpansionFDA agreement establishes a defined pediatric development framework before a potential biologics license submission. It expands AP-SA02’s addressable patient population and reduces regulatory uncertainty for future studies in children with severe infections.

Non-Dilutive FundingFederal non-dilutive funding supports AP-SA02 development while reducing reliance on immediate equity financing for selected activities. Continued DoD backing also provides external validation of the candidate’s relevance to antimicrobial resistance and military needs.

Bears Say

Negative Equity And LeverageNegative equity and meaningful debt leave Armata with limited balance-sheet protection as it funds late-stage development. This weakens financial flexibility and increases the likelihood that future capital needs could involve costly or dilutive financing.

Persistent Cash BurnArmata continues to consume substantial cash because development operations are not self-funding. Even with some moderation in free-cash-flow deterioration, ongoing negative cash generation means additional external capital will likely be needed to sustain trials.

Limited Earnings PowerThe company has not established meaningful commercial revenue or earnings power, and its cost base remains far above revenue. Until a product reaches approval and adoption, profitability depends on successful development, regulatory progress, and future financing.

Armata Pharmaceuticals News

Armata: Buy Rating Reiterated as AP-SA02 Advances Toward 2H26 Phase 3 Start; $15 Price Target Maintained

Armata Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from...

15d ago

ARMP

Armata Pharmaceuticals Promotes David House to CFO

An announcement from Armata Pharmaceuticals ( ($ARMP) ) is now available. On July 17, 2026, Armata Pharmaceuticals’ board...

1M ago

ARMP

Armata Advances AP-SA02 Toward Phase 3 Trial Launch

An update from Armata Pharmaceuticals ( ($ARMP) ) is now available. On July 20, 2026, Armata Pharmaceuticals reported...

1M ago

ARMP

Armata provides update on AP-SA02 studies

Armata Pharmaceuticals (ARMP) announced significant clinical, regulatory, manufacturing and operational progress supporting advancement of AP-SA02, the Company’s intravenously...

1M ago

ARMP

Armata promotes David House to CFO

Armata announced the promotion of David House to CFO. House has served as the Company’s Senior Vice President,...

1M ago

ARMP

FDA Pediatric Plan Milestone and Phase 3 Design Support Unchanged $15 Price Target and Buy Rating on Armata (ARMP)

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Armata Pharmaceuticals, retaining the price target of...

2M ago

ARMP

Armata Advances AP-SA02 Pediatric Plan With FDA Agreement

Armata Pharmaceuticals ( ($ARMP) ) has shared an announcement. On July 13, 2026, Armata Pharmaceuticals announced that the...

2M ago

ARMP

Armata Pharmaceuticals reaches agreement with FDA on iPSP for AP-SA02

Armata Pharmaceuticals (ARMP) announced that it has received agreement from the U.S. FDA on an Agreed Initial Pediatric...

2M ago

ARMP

Armata Pharmaceuticals granted $2.5M additional non-dilutive award funding

Armata Pharmaceuticals (ARMP) has received an additional $2.5M of non-dilutive funding pursuant to a previously announced Department of...

2M ago

ARMP

Armata gains new DoD funding for AP-SA02 advancement

Armata Pharmaceuticals ( ($ARMP) ) has provided an update. On June 23, 2026, Armata Pharmaceuticals announced it received...

2M ago

ARMP

Armata Shareholders Approve Directors, Executive Pay and Auditor

Armata Pharmaceuticals ( ($ARMP) ) has provided an announcement. At its June 11, 2026 annual shareholder meeting, Armata...

2M ago

ARMP

Analyst Reiterates Buy on Armata, Maintaining $20 Price Target Ahead of Pivotal Phase 3 AP-SA02 Trial

JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on ARMP stock, giving a Buy rating on May...

3M ago

ARMP

Armata Secures New Loan Amid Wider Quarterly Loss

Armata Pharmaceuticals ( ($ARMP) ) has provided an update. On May 13, 2026, Armata reported first-quarter 2026 results...

4M ago

ARMP

Armata Pharmaceuticals reports Q1 EPS ($3.16) vs. (20c) last year

Reports Q1 revenue $0.8M vs. $0.5M last year. “Our top priority in 2026 is advancing Armata’s lead Staphylococcus...

4M ago

ARMP

TG1N FAQ

What was Armata Pharmaceuticals Inc’s price range in the past 12 months?

Armata Pharmaceuticals Inc lowest stock price was €1.97 and its highest was €12.70 in the past 12 months.

What is Armata Pharmaceuticals Inc’s market cap?

Armata Pharmaceuticals Inc’s market cap is €177.34M.

When is Armata Pharmaceuticals Inc’s upcoming earnings report date?

Armata Pharmaceuticals Inc’s upcoming earnings report date is Nov 18, 2026 which is in 82 days.

How were Armata Pharmaceuticals Inc’s earnings last quarter?

Armata Pharmaceuticals Inc released its earnings results on Aug 12, 2026. The company reported -€0.233 earnings per share for the quarter, beating the consensus estimate of -€0.384 by €0.151.

Is Armata Pharmaceuticals Inc overvalued?

According to Wall Street analysts Armata Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Armata Pharmaceuticals Inc pay dividends?

Armata Pharmaceuticals Inc does not currently pay dividends.

What is Armata Pharmaceuticals Inc’s EPS estimate?

Armata Pharmaceuticals Inc’s EPS estimate is -0.35.

How many shares outstanding does Armata Pharmaceuticals Inc have?

Armata Pharmaceuticals Inc has 37,181,980 shares outstanding.

What happened to Armata Pharmaceuticals Inc’s price movement after its last earnings report?

Armata Pharmaceuticals Inc reported an EPS of -€0.233 in its last earnings report, beating expectations of -€0.384. Following the earnings report the stock price went up 1.676%.

Which hedge fund is a major shareholder of Armata Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in DE:TG1N

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Armata Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-20.00%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Armata Pharmaceuticals Inc

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.

Armata Pharmaceuticals (TG1N) Earnings & Revenues

Historic Earnings Reports

TG1N Stock 12 Month Forecast

Average Price Target

€12.85

▲(183.12% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","4":"€4","7":"€7","10":"€10","13":"€13"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12.853448400000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€12.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.853448400000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€12.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.853448400000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€12.85</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4,7,10,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.12,4.7918037230769235,5.463607446153846,6.135411169230769,6.807214892307693,7.479018615384616,8.150822338461538,8.822626061538461,9.494429784615384,10.166233507692308,10.838037230769231,11.509840953846155,12.181644676923078,{"y":12.853448400000001,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.12,4.7918037230769235,5.463607446153846,6.135411169230769,6.807214892307693,7.479018615384616,8.150822338461538,8.822626061538461,9.494429784615384,10.166233507692308,10.838037230769231,11.509840953846155,12.181644676923078,{"y":12.853448400000001,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.12,4.7918037230769235,5.463607446153846,6.135411169230769,6.807214892307693,7.479018615384616,8.150822338461538,8.822626061538461,9.494429784615384,10.166233507692308,10.838037230769231,11.509840953846155,12.181644676923078,{"y":12.853448400000001,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.04,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.44,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.24,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.95,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.75,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.05,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.95,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >